Malaria and TB Vaccines

Malaria continues to claim an estimated 2 to 3 million lives annually and to account for untold morbidity in the approximately 300 to 500 million people infected annually. Malaria is considered a re-emerging disease, due largely to the spread of drug-resistant parasite strains, decay of health-care infrastructure and difficulties in implementing and maintaining vector control programs in many developing countries. Four species of protozoan parasites cause malaria in humans: Plasmodium falciparum, P. vivax, P. malariae, and P. ovale. P. falciparum is responsible for the majority of deaths and most of the severe forms of disease, including cerebral malaria. 

2 billion people latently infected with M. tuberculosis 5-10% infected people progress to disease 9 million new TB cases each year 1.5 million TB deaths each year Equivalent to 20 passenger aircraft crashes each day. TB is transmitted by adults with cavitatory disease HIV infected people carry greater burden of disease. Highest risk of progression from TB infection to active disease, and worst TB morbidity and mortality, compared to older children and adults.

  • Malaria in pregnancy: priorities for research
  • Malaria Vaccines for pregnants and newborns
  • Novel methods in TB vaccination

Related Conference of Malaria and TB Vaccines

July 27-28, 2018

31st Annual Congress on Vaccines, Clinical Trials & B2B

Vancouver, Canada
September 19-20, 2018

Annual Congress and Expo on Vaccines & Immunology

Amsterdam, Netherlands
October 22-23, 2018

30th World Congress on Vaccines and Immunization

Osaka, Japan

Malaria and TB Vaccines Conference Speakers

Recommended Sessions

Related Journals

Are you interested in